Ligand Pharmaceuticals (FRA:LGDN) Cyclically Adjusted Book per Share: €38.90 (As of Mar. 2026)


FRA:LGDN Ligand Pharmaceuticals Inc FRA:LGDN
73 GF Score
Price €266.00
GF Value €150.40
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Ligand Pharmaceuticals Cyclically Adjusted Book per Share?

Ligand Pharmaceuticals FRA:LGDN +1.53% 73 Cyclically Adjusted Book per Share is €38.90 as of Mar. 2026. GuruFocus rates FRA:LGDN with a GF Score™ of 73/100 and a GF Value™ of €150.40 (Significantly Overvalued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Ligand Pharmaceuticals's adjusted book value per share for the three months ended in Mar. 2026 was €43.072. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €38.90 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Ligand Pharmaceuticals's average Cyclically Adjusted Book Growth Rate was 10.80% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 13.80% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 19.20% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was 54.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Ligand Pharmaceuticals was 308.50% per year. The lowest was -18.00% per year. And the median was 20.75% per year.

As of today (2026-07-03), Ligand Pharmaceuticals's current stock price is €266.00. Ligand Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was €38.90. Ligand Pharmaceuticals's Cyclically Adjusted PB Ratio of today is 6.84.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Ligand Pharmaceuticals was 39.49. The lowest was 1.46. And the median was 4.25.


Ligand Pharmaceuticals  (FRA:LGDN) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Ligand Pharmaceuticals's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=266.00/38.90
=6.84

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Ligand Pharmaceuticals was 39.49. The lowest was 1.46. And the median was 4.25.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Ligand Pharmaceuticals Cyclically Adjusted Book per Share Related Terms


Ligand Pharmaceuticals Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Ligand Pharmaceuticals's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ligand Pharmaceuticals Cyclically Adjusted Book per Share Chart

Ligand Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 22.78 28.20 31.28 38.57 38.39

Ligand Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 38.64 35.93 35.65 38.39 38.90

FRA:LGDN vs DFTX, CGON, XENE: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Ligand Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ligand Pharmaceuticals Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ligand Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Ligand Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.


FRA:LGDN
73GF Score
Ligand Pharmaceuticals Inc FRA:LGDN
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ligand Pharmaceuticals Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Ligand Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=43.072/330.2130*330.2130
=43.072

Current CPI (Mar. 2026) = 330.2130.

Ligand Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201606 16.727 241.018 22.917
201609 15.791 241.428 21.598
201612 16.814 241.432 22.997
201703 17.758 243.801 24.052
201706 17.310 244.955 23.335
201709 16.894 246.819 22.602
201712 16.727 246.524 22.405
201803 18.928 249.554 25.046
201806 25.151 251.989 32.959
201809 28.419 252.439 37.175
201812 23.743 251.233 31.207
201903 48.605 254.202 63.139
201906 47.534 256.143 61.280
201909 43.975 256.759 56.555
201912 41.046 256.974 52.744
202003 37.322 258.115 47.747
202006 38.402 257.797 49.189
202009 36.819 260.280 46.712
202012 36.271 260.474 45.982
202103 37.623 264.877 46.903
202106 39.147 271.696 47.578
202109 41.315 274.310 49.735
202112 43.343 278.802 51.335
202203 42.715 287.504 49.060
202206 44.961 296.311 50.105
202209 48.802 296.808 54.295
202212 33.274 296.797 37.020
202303 35.232 301.836 38.544
202306 35.367 305.109 38.277
202309 35.923 307.789 38.540
202312 36.611 306.746 39.412
202403 41.397 312.332 43.767
202406 39.781 314.175 41.812
202409 40.400 315.301 42.311
202412 41.509 315.605 43.430
202503 38.175 319.799 39.418
202506 37.007 322.561 37.885
202509 41.186 324.800 41.872
202512 43.931 324.054 44.766
202603 43.072 330.213 43.072

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of €38.90 mean?
Ligand Pharmaceuticals (FRA:LGDN) has a Cyclically Adjusted Book per Share of €38.90 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Ligand Pharmaceuticals and its competitors.
Is Ligand Pharmaceuticals' Cyclically Adjusted Book per Share too high?
Ligand Pharmaceuticals' current Cyclically Adjusted Book per Share is €38.90. Overall, Ligand Pharmaceuticals has a GF Score™ of 73/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ligand Pharmaceuticals' Cyclically Adjusted Book per Share compare to DFTX and CGON?
Ligand Pharmaceuticals' Cyclically Adjusted Book per Share of €38.90 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Ligand Pharmaceuticals and its competitors. Ligand Pharmaceuticals's current Cyclically Adjusted Book per Share is €38.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ligand Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Ligand Pharmaceuticals (FRA:LGDN) is currently considered Significantly Overvalued. The stock's GF Value™ is €150.40, compared to a current price of €266.00 — trading 76.9% above its estimated fair value. The current Cyclically Adjusted Book per Share is €38.90. Ligand Pharmaceuticals' overall GF Score™ is 73/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Ligand Pharmaceuticals (FRA:LGDN), the current Cyclically Adjusted Book per Share is €38.90 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ligand Pharmaceuticals (FRA:LGDN) Overvalued in 2026?

Based on GuruFocus' analysis, Ligand Pharmaceuticals stock appears to be overvalued. The current stock price of €266.00 is trading 76.9% above its estimated GF Value™ of €150.40. GuruFocus considers Ligand Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for FRA:LGDN:

  • Cyclically Adjusted Book per Share: €38.90
  • GF Value™: €150.40 vs. price of €266.00 (76.9% above fair value)
  • GF Score™: 73/100 with 5 warning signs

No single metric tells the full story. See the FRA:LGDN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Ligand Pharmaceuticals Business Description

Other Exchanges LGND:USA
Address 555 Heritage Drive, Suite 200, Jupiter, FL, USA, 33458
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
73GF Score

Get the complete analysis for FRA:LGDN

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€266.00
Price
€150.40
GF Value